Differentiate Children Septic and Inflammatory Arthritis by Comparative Analysis
NCT03827759 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-04-24
Summary
The purpose is to found new biomarker that differentiate septic arthritis and Juvenile Idiopathic Arthritis in children. Synovial liquid and blood samples with proteomic, MiRNA searching, multiplex cytokine analysis and cellular phenotyping, will be analysed. The results for each data will be compared in function of the disease to search discriminant markers. On behalf with this result specific pathways could be identified .
Conditions
- Septic Arthritis
- Inflammatory Arthritis
- Children
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
University Hospital, Montpellier
lead OTHER
Principal Investigators
-
Eric JEZIORSKI, MD PhD · University Hospital, Montpellier
Eligibility
- Min Age
- 6 Months
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-02-04
- Primary Completion
- 2021-06-06
- Completion
- 2022-07-29
Countries
- France
Study Locations
More Related Trials
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
NCT07249060 ·Status: RECRUITING
-
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
NCT01436019 ·Status: UNKNOWN
-
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
NCT03575156 ·Status: COMPLETED ·Phase: NA
-
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases
NCT06757426 ·Status: NOT_YET_RECRUITING
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control
NCT02890147 ·Status: COMPLETED
-
Value of Tomosynthesis for the Detection of Sacro-iliitis (TOMOS SI)
NCT03689881 ·Status: UNKNOWN ·Phase: NA
-
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
NCT05961267 ·Status: COMPLETED
-
Circulating B-cell, Drug and Anti-drug Antibodies Monitoring in Patients Treated With Rituximab for Autoimmune Disorders
NCT07037732 ·Status: RECRUITING
-
Lymphocyte Sub-populations and Auto Immune Diseases
NCT03901664 ·Status: COMPLETED
-
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
NCT02922114 ·Status: COMPLETED ·Phase: NA
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort
NCT02890134 ·Status: COMPLETED
-
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:
NCT02890121 ·Status: COMPLETED
-
Anti-ficolin-3 Antibodies in Lupus Nephritis
NCT03842787 ·Status: COMPLETED
-
Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus
NCT04293510 ·Status: UNKNOWN
-
Prediction of Outcome of Lupus Nephritis
NCT02403115 ·Status: UNKNOWN
-
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
NCT05383339 ·Status: RECRUITING
-
PRediction Of Flares In Lupus With autoantibodiEs and Chemokines
NCT04951427 ·Status: UNKNOWN
-
Catalytic Antibodies and Lupus in Martinique
NCT01157468 ·Status: COMPLETED
-
Molecular Diagnosis of Systemic Autoinflammatory Diseases
NCT05364294 ·Status: RECRUITING
-
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
NCT06445127 ·Status: TERMINATED
-
Systemic Lupus Erythematosus and Accelerated Aging
NCT05698173 ·Status: RECRUITING ·Phase: NA
-
Rituximab in Patients With Acute Rheumatic Fever
NCT05682196 ·Status: SUSPENDED ·Phase: PHASE2
-
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
NCT05251415 ·Status: RECRUITING
-
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
NCT07069972 ·Status: NOT_YET_RECRUITING